Skip to main content
. 2019 Mar 20;5(3):eaav5010. doi: 10.1126/sciadv.aav5010

Fig. 2. Schematic illustration of DCL structure and biomechanisms of complementary targeting strategy.

Fig. 2

(A) The design of the proof-of-principle binary DCL for TNBC. (B) DCL increases cellular binding using precisely matched, multivalent ligand-receptor interactions. (C) DCL enhances internalization using cooperative ICAM1 and EGFR endocytosis pathways. (D) DCL improves therapeutic efficacy using synergistic blockade of ICAM1 and EGFR signaling cascades.